Tysabri found to maintain remission in Crohn's patients
Pharmaceutical Business Review - USA
Elan Corporation and Biogen Idec have reported research that suggests that their drug Tysabri can provide sustained remission in Crohn's disease patients for ...
See all stories on this topic

News Page 3 : Elan off Q3 targets
Irish Independent - Dublin,Ireland
... shortages of the drug. Revenue at Elan, which reintroduced its multiple sclerosis treatment Tysabri in the summer, fell 4pc to $123.3m.
See all stories on this topic

rituximab Multiple Sclerosis

Millennium Pharmaceuticals Q3 2006 Earnings Call Transcript
Seeking Alpha - New York,NY,USA
... III trial of VELCADE in combination with Rituximab in follicular ... significant with applications in rheumatoid arthritis, multiple sclerosis, chronic obstructive ...